The level of EGFR expression and the presence of mutations in signaling molecules downstream of the EGFR pathway have been reported to be determining factors for cetuximab responsiveness in patients with colorectal cancer; however, limited data have been reported for patients with HNSCC. Here, EGFR is linked to head and neck squamous cell carcinoma.